Johnson & Johnson (JNJ) Gross Margin
- Gross margin · 12 months: Value 67.91%; Formula and calculation Gross profit / revenue. Period ending 2026-06-28..
Gross margin
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 67.91% | Gross profit / revenue. Period ending 2026-06-28. $66.50B ÷ $97.93B × 100 ≈ 67.91% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 66.50B USD | Gross Profit |
| Revenue | 97.93B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 31.43B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-28 | $66.50B | $97.93B | $31.43B | 67.91% |
| 2026-03-29 | $65.36B | $96.36B | $31.00B | 67.82% |
| 2025-12-28 | $63.94B | $94.19B | $30.26B | 67.88% |
| 2025-09-28 | $62.73B | $92.15B | $29.42B | 68.08% |
| 2025-06-29 | $61.55B | $90.63B | $29.08B | 67.92% |
| 2025-03-30 | $61.01B | $89.33B | $28.32B | 68.30% |
| 2024-12-29 | $61.35B | $88.82B | $27.47B | 69.07% |
| 2024-09-29 | $60.55B | $87.70B | $27.14B | 69.05% |
| 2024-06-30 | $59.79B | $86.58B | $26.78B | 69.06% |
| 2024-03-31 | $59.27B | $85.65B | $26.38B | 69.20% |
| 2023-12-31 | $58.61B | $85.16B | $26.55B | 68.82% |
| 2023-10-01 | $66.32B | $98.66B | $32.33B | 67.23% |
| 2023-07-02 | $65.59B | $97.77B | $32.18B | 67.09% |
| 2023-04-02 | $64.38B | $96.26B | $31.89B | 66.88% |
| 2023-01-01 | $63.85B | $94.94B | $31.09B | 67.26% |
| 2022-10-02 | $64.76B | $96.04B | $31.28B | 67.43% |
| 2022-07-03 | $64.87B | $95.59B | $30.72B | 67.86% |
| 2022-04-03 | $64.49B | $94.88B | $30.39B | 67.97% |
| 2022-01-02 | $63.92B | $93.78B | $29.86B | 68.16% |
| 2021-10-03 | $61.73B | $91.45B | $29.71B | 67.51% |
| 2021-07-04 | $59.75B | $89.19B | $29.44B | 67.00% |
| 2021-04-04 | $55.79B | $84.21B | $28.43B | 66.24% |
| 2021-01-03 | $54.16B | $82.58B | $28.43B | 65.58% |
| 2020-09-27 | $53.11B | $80.86B | $27.75B | 65.68% |
| 2020-06-28 | $52.86B | $80.50B | $27.64B | 65.66% |
| 2020-03-29 | $54.73B | $82.73B | $28.00B | 66.15% |
| 2019-12-29 | $54.50B | $82.06B | $27.56B | 66.42% |
| 2019-09-29 | $54.32B | $81.71B | (m) | 66.49% |
| 2019-06-30 | $54.22B | $81.33B | (m) | 66.67% |
| 2019-03-31 | $54.50B | $81.59B | (m) | 66.80% |
| 2018-12-30 | $54.49B | $81.58B | (m) | 66.79% |
| 2018-09-30 | $54.08B | (m) | (m) | (m) |
| 2018-07-01 | $53.04B | (m) | (m) | (m) |
| 2018-04-01 | $52.13B | (m) | (m) | (m) |
| 2017-12-31 | $51.10B | (m) | (m) | (m) |
| 2017-10-01 | $50.72B | (m) | (m) | (m) |
| 2017-07-02 | $50.30B | (m) | (m) | (m) |
| 2017-04-02 | $50.43B | (m) | (m) | (m) |
| 2017-01-01 | $50.20B | (m) | (m) | (m) |
| 2016-10-02 | $49.77B | (m) | (m) | (m) |
| 2016-07-03 | $49.31B | (m) | (m) | (m) |
| 2016-04-03 | $48.60B | (m) | (m) | (m) |
| 2016-01-03 | $48.54B | (m) | (m) | (m) |
| 2015-09-27 | $48.80B | (m) | (m) | (m) |
| 2015-06-28 | $49.99B | (m) | (m) | (m) |
| 2015-03-29 | $51.02B | (m) | (m) | (m) |
| 2014-12-28 | $51.59B | (m) | (m) | (m) |
| 2014-09-28 | $51.58B | (m) | (m) | (m) |
| 2014-06-29 | $50.75B | (m) | (m) | (m) |
| 2014-03-30 | $49.68B | (m) | (m) | (m) |
| 2013-12-29 | $48.97B | (m) | (m) | (m) |
| 2013-09-29 | $48.13B | (m) | (m) | (m) |
| 2013-06-30 | $47.35B | (m) | (m) | (m) |
| 2013-03-31 | $46.29B | (m) | (m) | (m) |
| 2012-12-30 | $45.57B | (m) | (m) | (m) |
| 2012-09-30 | $44.93B | (m) | (m) | (m) |
| 2012-07-01 | $44.41B | (m) | (m) | (m) |
| 2012-04-01 | $44.50B | (m) | (m) | (m) |
| 2012-01-01 | $44.67B | (m) | (m) | (m) |
| 2011-10-02 | $44.36B | (m) | (m) | (m) |
| 2011-07-03 | $43.81B | (m) | (m) | (m) |
| 2011-04-03 | $43.09B | (m) | (m) | (m) |
| 2011-01-02 | $42.80B | (m) | (m) | (m) |
| 2010-10-03 | $43.43B | (m) | (m) | (m) |
| 2010-07-04 | $43.69B | (m) | (m) | (m) |
| 2010-04-04 | $43.78B | (m) | (m) | (m) |
| 2010-01-03 | $43.45B | (m) | (m) | (m) |
| 2009-09-27 | (m) | (m) | (m) | (m) |
| 2009-06-28 | (m) | (m) | (m) | (m) |
| 2009-03-29 | (m) | (m) | (m) | (m) |
| 2008-12-28 | $45.24B | (m) | (m) | (m) |
| 2008-09-28 | (m) | (m) | (m) | (m) |
| 2008-06-29 | (m) | (m) | (m) | (m) |
| 2007-12-30 | $43.34B | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |